SEC Form 4 · accession 0001209191-18-005377
NovoCure Ltd · NVCR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Asaf Danziger
Officer — Chief Executive Officer · Director
Period of report
Jan 23, 2018
Accepted (ET)
Jan 25, 2018 · 4:26 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001645113
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Jan 23, 2018 | S | 10,248 | $22.033 | D | 387,820 | D | |
| Ordinary SharesF2 | Jan 24, 2018 | S | 10,600 | $22.1705 | D | 377,220 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On January 23, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 10,248 shares in multiple trades at prices ranging from $22.00 to $22.15. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
- F2On January 24, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 10,600 shares in multiple trades at prices ranging from $22.00 to $22.45. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.